Date: Wednesday, September 5, 2018
Venue: Roppongi Hills Club,
Club room 1, (51st Floor)
Speaker: Dr. Makoto Suematsu, MD, PhD, President,
Japan Agency for Medical Research and Development (AMED)
Hosting Committees: Healthcare;
Medical Devices and Diagnostics; Pharmaceuticals;
Regenerative Medicine and Bioscience
Member Fee: ¥6,900
Guest Fee: ¥8,900
Deadline: Friday, August 31 (Noon)
The Japan Agency for Medical Research and Development (AMED) was established on April 1, 2015, for the purpose of improving medicine through research and development in Japan. The goal is to fast-track medical research and development (R&D) that directly benefits people—not only by extending life spans, but also by improving quality of life.
AMED engages in R&D in the field of medicine, establishes and maintains an environment for medical R&D, and provides funding to promote integrated medical R&D. This includes everything from basic research to practical applications to smoothly achieving the application of outcomes, as well as the comprehensive and effective establishment and maintenance of the R&D environment.
AMED’s role is to provide a one-stop service for research expenditures by consolidating research budgets, which had been previously allocated from a number of different sources: the Ministry of Education, Culture, Sports, Science and Technology; the Ministry of Health, Labour and Welfare; and the Ministry of Economy, Trade and Industry. AMED aims to achieve the world’s highest level of medical care and service. By promoting integrated research and development—from basic research to practical application—and by promoting growth in medical R&D, AMED works to build a society in which people live long, healthy lives.
Dr. Makoto Suematsu, founding and current president of AMED, will provide his update on AMED’s many activities, challenges, and accomplishments since its establishment two years ago, and will provide an overview of his bold vision for the way forward. Japan is a leader in medical research, and AMED was established as the “control tower” for targeted R&D funding allocation and a catalyst for future innovation. Much has happened since the founding of AMED. If you are in the healthcare industry, this is one event you will not want to miss!
This event is co-hosted by the ACCJ, the European Business Council (EBC), and the Pharmaceutical Research and Manufacturers of America (PhRMA).
ACCJ Healthcare Committee
John W. Carlson III, Chair
William Bishop, Andrew Joyce, Yuko Kidoguchi, Takeo Morooka, Toshio Nagase, R. Byron Sigel, Mika Shirai, Vice-Chairs
ACCJ Medical Devices and Diagnostics Subcommittee
William Bishop, Chair
Marie Kissel, Yasuhiko Amano, Jun Sekiguchi, Vice-Chairs
ACCJ Pharmaceuticals Subcommittee
Takeo Morooka, Chair
Regenerative Medicine and Bioscience Subcommittee
Yaju Hiromichi, Chair
Satoshi Tanaka, Vice-Chair
NOTE 1: This event is ON THE RECORD.
NOTE 2: If you cancel after the stated deadline, the full meeting fee will be charged to your account. All guests must be accompanied by an ACCJ member. Sorry, no substitutions or walk-ins.